25 May 2013
Keywords: Bayer, Rivaroxaban, Xarelto, Johnson & Johnson, EME, FDA
Article | 06 January 2011
German drug major Bayer (BAY: DE) has submitted an application for marketing authorization to the European Medicines Agency (EMA) for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
6 January 2011
24 May 2013
© 2013 thepharmaletter.com